120 related articles for article (PubMed ID: 36807183)
21. FOLFOX plus panitumumab or FOLFOX alone as additive therapy following R0/1 resection of RAS wild-type colorectal cancer liver metastases - The PARLIM trial (AIO KRK 0314).
Modest DP; Karthaus M; Kasper S; Moosmann N; Keitel V; Kiani A; Uhlig J; Jacobasch L; Fischer V Weikersthal L; Fuchs M; Kaiser F; Lerchenmüller C; Sent D; Junghanß C; Held S; Lorenzen S; Kaczirek K; Jung A; Stintzing S; Heinemann V
Eur J Cancer; 2022 Sep; 173():297-306. PubMed ID: 35970102
[TBL] [Abstract][Full Text] [Related]
22. Triplet Chemotherapy (FOLFOXIRI) Plus Bevacizumab Versus Doublet Chemotherapy (FOLFOX/FOLFIRI) Plus Bevacizumab in Conversion Therapy for Metastatic Colorectal Cancer: a Meta-Analysis.
Shui L; Wu YS; Lin H; Shui P; Sun Q; Chen X
Cell Physiol Biochem; 2018; 48(5):1870-1881. PubMed ID: 30092572
[TBL] [Abstract][Full Text] [Related]
23. FOLFOXIRI Plus Bevacizumab as Conversion Therapy for Patients With Initially Unresectable Metastatic Colorectal Cancer: A Systematic Review and Pooled Analysis.
Tomasello G; Petrelli F; Ghidini M; Russo A; Passalacqua R; Barni S
JAMA Oncol; 2017 Jul; 3(7):e170278. PubMed ID: 28542671
[TBL] [Abstract][Full Text] [Related]
24. XELOX plus bevacizumab vs. FOLFIRI plus bevacizumab treatment for first-line chemotherapy in metastatic colon cancer: a retrospective study of the Anatolian Society of Medical Oncology.
Duran AO; Karaca H; Besiroglu M; Bayoglu IV; Menekse S; Yapici HS; Yazilitas D; Bahceci A; Uysal M; Sevinc A; Hacibekiroglu I; Aksoy A; Tanriverdi O; Arpaci E; Inanc M; Dane F; Ozkan M
Asian Pac J Cancer Prev; 2014; 15(23):10375-9. PubMed ID: 25556478
[TBL] [Abstract][Full Text] [Related]
25. First-line panitumumab plus FOLFOX4 or FOLFIRI in colorectal cancer with multiple or unresectable liver metastases: A randomised, phase II trial (PLANET-TTD).
Carrato A; Abad A; Massuti B; Grávalos C; Escudero P; Longo-Muñoz F; Manzano JL; Gómez A; Safont MJ; Gallego J; García-Paredes B; Pericay C; Dueñas R; Rivera F; Losa F; Valladares-Ayerbes M; González E; Aranda E;
Eur J Cancer; 2017 Aug; 81():191-202. PubMed ID: 28633089
[TBL] [Abstract][Full Text] [Related]
26. [A Case of Ascending Colon Cancer with Synchronous Liver Metastases and Peritoneal Dissemination].
Mito M; Kameyama H; Shimada Y; Yamada S; Hotta S; Hirose Y; Yagi R; Tajima Y; Nakano M; Okamura T; Nakano M; Ichikawa H; Nagahashi M; Sakata J; Wakai T
Gan To Kagaku Ryoho; 2017 Nov; 44(12):1126-1128. PubMed ID: 29394555
[TBL] [Abstract][Full Text] [Related]
27. [Two Cases of Metastatic Rectal Cancer Patients Who Received Chemotherapy with FOLFOXIRI plus Bevacizumab].
Nishii T; Uchima Y; Yamakoshi Y; Wang E; Nagashima D; Hirakawa T; Aomatsu N; Iwauchi T; Morimoto J; Nakazawa K; Tei S; Takeuchi K
Gan To Kagaku Ryoho; 2016 Nov; 43(12):1705-1707. PubMed ID: 28133105
[TBL] [Abstract][Full Text] [Related]
28. A Randomized Phase II Study of Perioperative Chemotherapy Plus Bevacizumab Versus Postoperative Chemotherapy Plus Bevacizumab in Patients With Upfront Resectable Hepatic Colorectal Metastases.
Chun YJ; Kim SG; Lee KW; Cho SH; Kim TW; Baek JY; Park YS; Hong S; Chu CW; Beom SH; Jung M; Shin SJ; Ahn JB
Clin Colorectal Cancer; 2020 Sep; 19(3):e140-e150. PubMed ID: 32402681
[TBL] [Abstract][Full Text] [Related]
29. [A case of ascending colon cancer successfully treated for synchronous liver metastases with mFOLFOX6 after a resection of the primary tumor].
Tomochika S; Hazama S; Nakatsu H; Yoshida S; Tokuhisa Y; Yoshino S; Oka M
Gan To Kagaku Ryoho; 2009 Nov; 36(12):2184-6. PubMed ID: 20037364
[TBL] [Abstract][Full Text] [Related]
30. Randomized controlled trial of cetuximab plus chemotherapy for patients with KRAS wild-type unresectable colorectal liver-limited metastases.
Ye LC; Liu TS; Ren L; Wei Y; Zhu DX; Zai SY; Ye QH; Yu Y; Xu B; Qin XY; Xu J
J Clin Oncol; 2013 Jun; 31(16):1931-8. PubMed ID: 23569301
[TBL] [Abstract][Full Text] [Related]
31. Preoperative Chemotherapy with Bevacizumab Extends Disease-free Survival After Resection of Liver Metastases from Colorectal Cancer.
Umehara M; Umehara Y; Takahashi K; Murata A; Nishikawa S; Tokura T; Matsuzaka M; Tanaka R; Morita T
Anticancer Res; 2016 Apr; 36(4):1949-54. PubMed ID: 27069185
[TBL] [Abstract][Full Text] [Related]
32. [Efficacy and safety of bevacizumab (BEV) plus chemotherapeutic agents in the treatment of metastatic colorectal cancer, mCRC].
Guo X; Liu TS; Yu YY; Zhou YH; Chen Y; Zhuang RY; Cui YH
Zhonghua Zhong Liu Za Zhi; 2013 Aug; 35(8):604-7. PubMed ID: 24314219
[TBL] [Abstract][Full Text] [Related]
33. [A case of rectal cancer with multiple liver metastases successfully treated by repeated hepatectomy].
Ando M; Imai K; Matsunaga Y; Ami K; Ganno H; Amagasa H; Ohshima N; Fukuda A; Nagahama T; Aoki N; Fujiya K; Arai K; Tei S; Okada Y
Gan To Kagaku Ryoho; 2014 Nov; 41(12):1791-3. PubMed ID: 25731331
[TBL] [Abstract][Full Text] [Related]
34. Cost-effectiveness of targeted therapy with cetuximab in patients with K-ras wild-type colorectal cancer presenting with initially unresectable metastases limited to the liver in a German setting.
Asseburg C; Frank M; Köhne CH; Hartmann JT; Griebsch I; Mohr A; Osowski U; Schulten J; Mittendorf T
Clin Ther; 2011 Apr; 33(4):482-97. PubMed ID: 21635994
[TBL] [Abstract][Full Text] [Related]
35. Conversion to complete resection with mFOLFOX6 with bevacizumab or cetuximab based on K-ras status for unresectable colorectal liver metastasis (BECK study).
Hatano E; Okuno M; Nakamura K; Ishii T; Seo S; Taura K; Yasuchika K; Yazawa T; Zaima M; Kanazawa A; Terajima H; Kaihara S; Adachi Y; Inoue N; Furumoto K; Manaka D; Tokka A; Furuyama H; Doi K; Hirose T; Horimatsu T; Hasegawa S; Matsumoto S; Sakai Y; Uemoto S
J Hepatobiliary Pancreat Sci; 2015 Aug; 22(8):634-45. PubMed ID: 25926024
[TBL] [Abstract][Full Text] [Related]
36. Prospective pilot study of neoadjuvant chemotherapy with 5-fluorouracil, folinic acid and oxaliplatin in resectable liver metastases of colorectal cancer. Analysis of 42 neoadjuvant chemotherapies.
Lorenz M; Staib-Sebler E; Gog C; Proschek D; Jauch KW; Ridwelski K; Hohenberger W; Gassel HJ; Lehmann U; Vestweber KH; Padberg W; Zamzow K; Müller HH
Zentralbl Chir; 2003 Feb; 128(2):87-94. PubMed ID: 12632273
[TBL] [Abstract][Full Text] [Related]
37. [A Case of Neuroendocrine Carcinoma of the Ascending Colon That Responded Completely to Chemotherapy].
Satake M; Yoshimatsu K; Ito Y; Imaizumi R; Sano M; Kodera A; Miyano Y; Koike T; Yamada Y; Okayama S; Yokomizo H; Usui T; Yamaguchi K; Shiozawa S; Shimakawa T; Katsube T; Naritaka Y
Gan To Kagaku Ryoho; 2018 Oct; 45(10):1513-1515. PubMed ID: 30382062
[TBL] [Abstract][Full Text] [Related]
38. [Liver damage detected after a hepatectomy for liver metastasis after 12 courses of mFOLFOX6 therapy as an adjuvant chemotherapy for colorectal cancer].
Makino S; Murata K; Murakami M; Wada Y; Kato R; Nishigaki T; Owada Y; Okada K; Yanagisawa T; Okamura S; Ebisui C; Yokouchi H; Kinuta M; Nakagomi N; Tamai M
Gan To Kagaku Ryoho; 2012 Nov; 39(12):2222-4. PubMed ID: 23268030
[TBL] [Abstract][Full Text] [Related]
39. Partial response after treatment with Conversion chemotherapy: A case report of a patient with colon cancer and unresectable hepatic metastases.
Bu Z; Lu C; Yang X; Lai H; Jiang Y; Li Y; Lin Y; Qin Y; Xiao M; Cheng C; Liu Q
Medicine (Baltimore); 2019 Apr; 98(17):e15239. PubMed ID: 31027071
[TBL] [Abstract][Full Text] [Related]
40. Histological liver injury and surgical outcome after FOLFOX followed by a hepatectomy for colorectal liver metastases in Japanese patients.
Komori H; Beppu T; Baba Y; Horino K; Imsung C; Masuda T; Hayashi H; Okabe H; Ootao R; Watanabe M; Takamori H; Iyama K; Baba H
Int J Clin Oncol; 2010 Jun; 15(3):263-70. PubMed ID: 20238233
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
